Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:INFU NASDAQ:NNOX NASDAQ:PYPD NASDAQ:SGHT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINFUInfuSystem$10.08-3.3%$7.79$4.61▼$11.04$205.89M1.82179,865 shs270,018 shsNNOXNano-X Imaging$3.79-5.1%$4.61$3.63▼$11.00$218.81M1.941.72 million shs798,017 shsPYPDPolyPid$3.46-0.7%$3.48$2.30▼$3.93$55.07M1.48202,274 shs17,266 shsSGHTSight Sciences$3.41-4.5%$3.80$2.03▼$7.03$178.58M2.46193,547 shs59,476 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINFUInfuSystem+1.56%-1.51%+18.01%+71.10%+72.52%NNOXNano-X Imaging-0.75%+5.56%-14.19%-26.25%-33.50%PYPDPolyPid+0.87%+2.35%+8.39%+0.87%-5.16%SGHTSight Sciences-3.25%-7.75%-15.80%-14.80%-44.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINFUInfuSystem$10.08-3.3%$7.79$4.61▼$11.04$205.89M1.82179,865 shs270,018 shsNNOXNano-X Imaging$3.79-5.1%$4.61$3.63▼$11.00$218.81M1.941.72 million shs798,017 shsPYPDPolyPid$3.46-0.7%$3.48$2.30▼$3.93$55.07M1.48202,274 shs17,266 shsSGHTSight Sciences$3.41-4.5%$3.80$2.03▼$7.03$178.58M2.46193,547 shs59,476 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINFUInfuSystem+1.56%-1.51%+18.01%+71.10%+72.52%NNOXNano-X Imaging-0.75%+5.56%-14.19%-26.25%-33.50%PYPDPolyPid+0.87%+2.35%+8.39%+0.87%-5.16%SGHTSight Sciences-3.25%-7.75%-15.80%-14.80%-44.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINFUInfuSystem 4.00Strong Buy$12.5024.01% UpsideNNOXNano-X Imaging 3.50Strong Buy$8.50124.45% UpsidePYPDPolyPid 3.17Buy$12.40257.97% UpsideSGHTSight Sciences 2.43Hold$4.4229.52% UpsideCurrent Analyst Ratings BreakdownLatest PYPD, INFU, NNOX, and SGHT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025SGHTSight SciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold8/21/2025SGHTSight SciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$3.60 ➝ $4.508/14/2025PYPDPolyPidCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.00 ➝ $13.008/14/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/13/2025NNOXNano-X ImagingD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $8.008/13/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.008/11/2025NNOXNano-X ImagingAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/8/2025SGHTSight SciencesLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$3.00 ➝ $5.007/22/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.007/21/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/15/2025SGHTSight SciencesMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$3.00 ➝ $4.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINFUInfuSystem$139.89M1.47$0.79 per share12.79$2.47 per share4.08NNOXNano-X Imaging$11.89M18.41N/AN/A$3.27 per share1.16PYPDPolyPidN/AN/AN/AN/A$0.75 per shareN/ASGHTSight Sciences$79.87M2.24N/AN/A$1.72 per share1.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINFUInfuSystem$870K$0.23168.0332.52N/A1.12%2.78%1.41%N/ANNOXNano-X Imaging-$53.52M-$0.90N/AN/AN/A-468.29%-32.09%-28.73%11/20/2025 (Estimated)PYPDPolyPid-$29.02M-$3.83N/A∞N/AN/A-453.95%-138.92%11/12/2025 (Estimated)SGHTSight Sciences-$51.51M-$0.96N/AN/AN/A-64.23%-59.38%-36.43%11/6/2025 (Estimated)Latest PYPD, INFU, NNOX, and SGHT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PYPDPolyPid-$0.53-$0.78-$0.25-$0.78N/AN/A8/12/2025Q2 2025NNOXNano-X Imaging-$0.15-$0.23-$0.08-$0.23$3.20 million$3.04 million8/7/2025Q2 2025SGHTSight Sciences-$0.25-$0.23+$0.02-$0.23$18.18 million$19.56 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINFUInfuSystemN/AN/AN/AN/AN/ANNOXNano-X ImagingN/AN/AN/AN/AN/APYPDPolyPidN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINFUInfuSystem0.501.981.59NNOXNano-X ImagingN/A4.194.03PYPDPolyPidN/A2.282.28SGHTSight Sciences0.5710.019.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINFUInfuSystem71.13%NNOXNano-X Imaging21.49%PYPDPolyPid26.47%SGHTSight Sciences55.51%Insider OwnershipCompanyInsider OwnershipINFUInfuSystem10.20%NNOXNano-X ImagingN/APYPDPolyPid24.70%SGHTSight Sciences28.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINFUInfuSystem41020.43 million19.10 millionOptionableNNOXNano-X Imaging19057.78 millionN/AOptionablePYPDPolyPid8015.90 million11.97 millionNo DataSGHTSight Sciences21052.37 million37.23 millionOptionablePYPD, INFU, NNOX, and SGHT HeadlinesRecent News About These CompaniesSight Sciences, Inc. (NASDAQ:SGHT) Receives $4.42 Average Target Price from AnalystsSeptember 10 at 2:33 AM | americanbankingnews.comSight Sciences, Inc.: Sight Sciences Announces the OMNI Surgical System to be Included in UnitedHealthcare's Expanded Coverage of Glaucoma Surgical TreatmentsSeptember 9 at 10:10 AM | finanznachrichten.deSight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical TreatmentsSeptember 9 at 10:10 AM | finance.yahoo.comSight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare's® Expanded Coverage of Glaucoma Surgical TreatmentsSeptember 9 at 7:05 AM | globenewswire.comSight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Rating of "Hold" from AnalystsSeptember 8 at 2:26 AM | marketbeat.comSight Sciences (NASDAQ:SGHT) Downgraded to "Sell" Rating by Wall Street ZenSeptember 8 at 2:41 AM | marketbeat.comSight Sciences (NASDAQ:SGHT) Stock Rating Lowered by Wall Street ZenSeptember 7 at 3:00 AM | americanbankingnews.comSight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJOSeptember 2, 2025 | globenewswire.comSight Sciences, Inc. $SGHT Shares Purchased by Long Focus Capital Management LLCSeptember 1, 2025 | marketbeat.comNeedham & Company LLC Reaffirms "Hold" Rating for Sight Sciences (NASDAQ:SGHT)August 30, 2025 | americanbankingnews.comSight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare ConferenceAugust 26, 2025 | globenewswire.comWhat 4 Analyst Ratings Have To Say About Sight SciencesAugust 22, 2025 | benzinga.comSight Sciences price target raised to $4.50 from $3.60 at CitiAugust 21, 2025 | msn.comSight Sciences, Inc. (NASDAQ:SGHT) Given Average Recommendation of "Hold" by BrokeragesAugust 14, 2025 | marketbeat.comSight Sciences’ Earnings Call: Balancing Growth and ChallengesAugust 13, 2025 | msn.comLake Street Upgrades Sight Sciences (SGHT)August 11, 2025 | msn.comWall Street Zen Upgrades Sight Sciences (NASDAQ:SGHT) to HoldAugust 10, 2025 | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | msn.comSight Sciences, Inc. (SGHT) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comSight Sciences Reports Q2 2025 Financial ResultsAugust 8, 2025 | tipranks.comCompared to Estimates, Sight Sciences (SGHT) Q2 Earnings: A Look at Key MetricsAugust 7, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025From Debt to Liftoff: EchoStar's $23 Billion CatalystBy Jeffrey Neal Johnson | August 27, 2025PYPD, INFU, NNOX, and SGHT Company DescriptionsInfuSystem NYSE:INFU$10.08 -0.34 (-3.26%) Closing price 03:59 PM EasternExtended Trading$10.08 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.Nano-X Imaging NASDAQ:NNOX$3.79 -0.20 (-5.09%) Closing price 03:59 PM EasternExtended Trading$3.81 +0.02 (+0.61%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source, and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists to provide, as well as customers to obtain remote interpretations of imaging data; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data included in images of existing computed tomography scans for osteoporosis and cardiovascular disease; Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities; and multi-specialty physician groups, contracts, and radiology readings. The company is headquartered in Petach Tikva, Israel.PolyPid NASDAQ:PYPD$3.46 -0.03 (-0.74%) Closing price 03:51 PM EasternExtended Trading$3.46 +0.00 (+0.03%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.Sight Sciences NASDAQ:SGHT$3.41 -0.16 (-4.48%) Closing price 03:59 PM EasternExtended Trading$3.41 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Forget QQQ: This ETF Marries the Magnificent 7 and Communications Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
